Fig. 2

The levels of soluble IgA and IgG in feces of active CD patients according to the Montreal classification. The levels of soluble IgA and IgG in feces of active CD patients were measured by ELISA, and clinical relevance to age, disease location, disease behavior, and perianal lesions was then evaluated, respectively. Soluble IgA and IgG production in feces of HC (n = 41), A1 CD (n = 14), A2 CD (n = 122), and A3 CD (n = 42) (a, b). Soluble IgA and IgG production in feces of HC (n = 41), L1 CD (n = 57), L2 CD (n = 49), and L3 CD (n = 72) (c, d). Soluble IgA and IgG production in feces of HC (n = 41), B1 CD (n = 99), B2 CD (n = 65), and B3 CD (n = 14) (e, f). Soluble IgA and IgG production in feces of HC (n = 41), PCD (n = 33), and CD (n = 145) (g, h). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001